<DOC>
	<DOCNO>NCT02834780</DOCNO>
	<brief_summary>The primary purpose study determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) H3B-6527 ( Part 1 ) , assess safety tolerability H3B-6527 single agent administer orally ( Part 2 ) participant advance hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Phase 1 Study Evaluate Safety , Pharmacokinetics Pharmacodynamics H3B-6527 Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion criterion : 1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 2 . Presence least one measurable lesion accord modify Response Evaluation Criteria Solid Tumors ( mRECIST ) 3 . Participants hepatocellular carcinoma progress despite standard therapy intolerant standard therapy Exclusion criterion : 1 . Participants brain subdural metastasis , unless previously treat stable 2 . Known human immunodeficiency virus ( HIV ) infection 3 . Previous treatment Fibroblast growth factor receptor 4 ( FGFR4 ) target therapy 4 . Presence gastric esophageal varix require active treatment 5 . Significant cardiovascular impairment major illness 6 . Females pregnant breastfeed Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Hepatocellular Carcinoma</keyword>
	<keyword>H3B-6527</keyword>
</DOC>